FDA approves first gene therapy in the United States – Pharmacy Today, American Pharmacists Association, pharmacist.com
|
FDA approves first gene therapy in the United States
Pharmacy Today, American Pharmacists Association, pharmacist.com FDA has approved the first gene therapy in the United States, tisagenlecleucel (Kymriah—Novartis), ushering in a new approach to treatment of cancer and other serious and life-threatening diseases, said the agency in a recent news release. |
Medical Xpress |
Zika virus kills brain cancer stem cells; could potentially be used to treat deadly disease
Medical Xpress Brain cancer stem cells (left) are killed by Zika virus infection (image at right shows cells after Zika treatment). A new study shows that the virus, known for killing cells in the brains of developing fetuses, could be redirected to …more. While … Zika kills brain cancer cells, may find use as therapyThe San Diego Union-Tribune Zika virus used to treat aggressive brain cancerBBC News Could the Zika virus be harnessed to treat brain cancer?Medical News Today Philly.com –ResearchGate (blog) –Alphr all 16 news articles » |
|
Gilead Sciences Couldn’t Have Timed its Splash Into CAR–T Better
Motley Fool The FDA approved the world’s first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion. …. and reengineer them in a certain … |
|
Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma’s CAR–T Therapy Axicabtagene Ciloleucel
PR Newswire (press release) Jerrell Shelton, CEO of Cryoport, stated, “Kite’s CAR T-cell therapy for non-Hodgkin lymphoma is based on pioneering science which uses the patients’ own immune cells to treat cancers. It offers hope to patients who previously had no other option left … |
|
Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma’s CAR–T Therapy Axicabtagene Ciloleucel
Markets Insider Jerrell Shelton, CEO of Cryoport, stated, “Kite’s CAR T-cell therapy for non-Hodgkin lymphoma is based on pioneering science which uses the patients’ own immune cells to treat cancers. It offers hope to patients who previously had no other option left … Gilead Sciences Couldn’t Have Timed its Splash Into CAR–T BetterMotley Fool |
Madison.com |
Why Juno Therapeutics Shares Vaulted 46% Higher in August
Madison.com The Kite Pharma deal comes ahead of an expected FDA decision on its CAR–T, axi-cel, on Nov. 29. It’s not a given that axi-cel will get a green light, but it delivered a better than 50% complete response rate in trials, and the FDA opted against holding … |
Xconomy |
Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR–T
Xconomy The FDA has forced Cellectis to shut down two Phase 1 trials it has been running to test an “off the shelf” type of cell therapy—a stinging setback to the France- and New York-based company’s aspirations to leapfrog other developers of CAR–T, a type … FDA hits Cellectis’ off-the-shelf CAR–T program with clinical hold after first patient treated in phase 1 trial diesFierceBiotech In staggering setback, toxic reaction kills Cellectis’ first CAR–T patient, forcing trial haltEndpoints News Cellectis Reports Clinical Hold of UCART123 StudiesBusiness Wire (press release) Reuters –pharmaphorum all 13 news articles » |